NeuroSense Therapeutics provided an update from its CEO, Alon Ben-Noon, on the Company’s clinical and operational developments during the second quarter of 2023.
Updates include –
- Strategic Scientific Agreement with Biogen
- Phase 2 Alzheimer’s Disease (AD) Trial Under Preparation
- Parkinson’s Disease (PD) Biomarker Study Completed
and more..
